Compare EQBK & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQBK | MNKD |
|---|---|---|
| Founded | 2002 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2015 | 2004 |
| Metric | EQBK | MNKD |
|---|---|---|
| Price | $49.79 | $3.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $51.33 | $8.69 |
| AVG Volume (30 Days) | 74.3K | ★ 4.2M |
| Earning Date | 04-14-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.06 | N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | $74.58 | $35.81 |
| Revenue Next Year | $5.11 | $11.89 |
| P/E Ratio | $24.14 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $38.60 | $2.23 |
| 52 Week High | $52.27 | $6.51 |
| Indicator | EQBK | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 48.70 |
| Support Level | $44.45 | $3.74 |
| Resistance Level | $50.07 | $4.23 |
| Average True Range (ATR) | 0.83 | 0.17 |
| MACD | -0.24 | -0.00 |
| Stochastic Oscillator | 31.77 | 45.30 |
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 77 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.